The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

Sep 22, 2013
195 Pages - Pub ID: KLI5123810
Abstract Table of Contents Search Inside Report Related Reports

The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment.

Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following:
  • Scientific Differences of Pharmaceuticals and Biopharmaceuticals
  • Market Share of Biosimilar Sales in Comparison to Brand Sales
  • Marketed Biologics with Expired Patents
  • Marketed Biologics with Active Patents
  • Cost Savings From Biosimilar Use
  • World Biosimilar Market Potential by Region 2010-2017
  • World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other)
  • Biosimilars Pipeline by Company and Product Type
For the purposes of this study, Kalorama has focused on the market for products which have lost patent in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals. Kalorama has identified the biopharmaceuticals that have lost patent protection and are the first products produced by generic companies. As part of its coverage, the following companies were profiled:
  • 3SBio, Inc
  • Actavis, Inc.
  • Apotex, Inc.
  • Beijing Four Rings Biopharmaceutical Co Ltd
  • Biocad
  • Biocon Ltd .
  • Bio Sidus S.A.
  • BioXpress Therapeutics S.A.
  • Boehringer Ingelheim Gmbh
  • Celltrion, Inc.
  • Dong-A Pharmaceutical
  • Dr. Reddy’s Laboratories Limited
  • Epirus Biopharmaceuticals
  • Gedeon Richter
  • Harvest Moon Pharmaceuticals USA,
  • Hospira, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Company
  • Momenta Pharmaceuticals Inc
  • Phage Pharmaceuticals, Inc.
  • Ranbaxy Laboratories Limited
  • Reliance GeneMedix PLC
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • TEVA Pharmaceutical Industries, Ltd.
  • Wockhardt Ltd.
  • Xiamen Amoytop Biotech Co Ltd.

Related Reports:

The World Market for Ultrasound Systems (Traditional, Portable, Handheld, Therapeutic Category Markets)
Jul 7, 2016 - KLI15049235 - $4,200.00

The World Market for Companion Diagnostic Tests
Jun 7, 2016 - KLI15021881 - $4,200.00

The World Market for Infusion Pumps (Large Volume Pumps, Ambulatory Pumps, Insulin Pumps, Enteral Feeding Pumps, Others)
Jun 6, 2016 - KLI15021669 - $4,200.00

Surgical Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, Mexico, Australia, Canada)
May 20, 2016 - KLI15006734 - $4,200.00

The Global Market for Medical Devices, 7th Edition
May 13, 2016 - KLI15002686 - $1,500.00

Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)
Mar 25, 2016 - KLI5948213 - $4,200.00

The World Market for Laboratory Information Systems
Feb 11, 2016 - KLI5881925 - $4,200.00

World In Vitro Diagnostics (IVD) Market Bundle: Molecular Diagnostics (Microbiology, Oncology, Blood, Prenatal, Inherited, Others), Cancer Diagnostics (HPV, ISH, Cytometry, PSA, FOB, Others), Infectious Diseases (ID/AST, POC, HAIs, STDs, Other)
Jan 22, 2016 - KLI5757702 - $3,995.00

The World Market for Microarrays
Jan 13, 2016 - KLI5827689 - $4,200.00

The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Immunological Disease Markers, Infectious Disease Markers, Others)
Dec 10, 2015 - KLI5789361 - $4,200.00

800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >

Live Chat Software
Most Popular Research
Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
Proteomics Markets for Clinical IVD Applications and Research Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies)
Library Preparation and Target Enrichment for Next Generation Sequencing Product Markets
Growth Potential of Specific Biomarker-Based Tests: White Paper
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets)
PCR-based Personalized Medicine Tests: White Paper
Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Home About Us My Account Personal Library Contact Us
Copyright © 2016 MarketResearch.com. All Rights Reserved.
A division of Market Research Group, LLC
7/24/2016 - 40
Contact Us: 800.298.5603 (U.S.)
or +1.240.747.3096 (Int'l)
Hours: Monday - Thursday: 5:30am - 6:30pm EST
Fridays: 5:30am - 5:30pm EST